Denali Therapeutics remains an intriguing clinical-stage biotech focused on neurodegenerative and lysosomal storage diseases.

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move ...

Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.

WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...

Health and Human Services Secretary Robert F. Kennedy's newly appointed CDC vaccine advisory panel reportedly has seven ...

A CDC report set to be presented on June 26 at a meeting of the agency's Advisory Committee on Immunization Practices finds ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Gena Wang of ...

The Health and Human Services secretary Robert F. Kennedy Jr's new vaccine advisory panel will discuss and vote on the use of ...

Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to ...

A newly appointed CDC advisory panel of vaccine experts is scheduled to meet later this month to vote on recommendations for flu shots containing a mercury-based preservative, according to a draft ...